Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T Bridging to Allo-HSCT for Severe Aplastic Anemia
NCT06633328Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA07 in aplastic anemia, sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
UTAA07
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06633328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633328.